Difference between revisions of "Team:ETH Zurich/Achievements"
Line 83: | Line 83: | ||
<li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, helped with a survey from <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">advice</a> when their transformations did not work.</li> | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, helped with a survey from <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">advice</a> when their transformations did not work.</li> | ||
− | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields, such as <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics"> | + | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields, such as <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">an expert from the ethics commission</a>, the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">founder of a start-up</a> or an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">expert in patents law</a> and <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">integrated the advice and ideas</a> we got from them into the <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Design">design</a>.</li> |
</ul> | </ul> | ||
<p></p> | <p></p> | ||
Line 127: | Line 127: | ||
<td><a href="http://parts.igem.org/Part:BBa_K1847000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="http://parts.igem.org/Part:BBa_K1847000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
+ | |||
<tr> | <tr> | ||
<td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/e/e8/ETH15_Silver_medal.png" width="70%"></img></td> | <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/e/e8/ETH15_Silver_medal.png" width="70%"></img></td> | ||
− | <td> | + | <td>These new parts we also submitted to the iGEM Parts Registry. </td> |
<td><a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
− | + | ||
+ | <td>We characterized <a href="https://2015.igem.org/wiki/index.php?title=Team:ETH_Zurich/Results#Characterization_of_the_lacI-lldR_promoter">two newly designed hybrid promoters</a> and were able to show an effective combined repression by LldR and LacI. According to our knowledge this has never been attempted before.</td> | ||
<td><a href=""><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href=""><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
− | <td>Human Practices in iGEM. | + | |
+ | <td>Our Human Practices Efforts: <li>We went to two different schools, thaught the children about what DNA is, performed experiments with them and published an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#_Newspaper_Articles_">article about it in the local newspaper</a>.</li> | ||
+ | |||
+ | <li>We told the ETH-student magacine <a href="http://www.vseth.ethz.ch/polykum/archiv#2014/2015">polykum</a> about iGEM and gave an interview.</li> | ||
+ | |||
+ | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, helped with a survey from <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">advice</a> when their transformations did not work.</li> | ||
+ | |||
+ | </td> | ||
<td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
<td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/9/9b/ETH15_Gold_medal.png" width="70%"></img></td> | <td rowspan="3"><img src="https://static.igem.org/mediawiki/2015/9/9b/ETH15_Gold_medal.png" width="70%"></img></td> | ||
− | <td> | + | <td>More Human Practices Efforts: |
+ | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields, such as <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">an expert from the ethics commission</a>, the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">founder of a start-up</a> or an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">expert in patents law</a> and <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">integrated the advice and ideas</a> we got from them into the <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Design">design</a>.</li> | ||
+ | </td> | ||
<td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="https://2015.igem.org/Team:ETH_Zurich/Practices"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
− | <td> | + | <td><li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Stockholm">collaborated</a> with the team from <a href="https://2015.igem.org/Team:Stockholm"> Stockholm</a> by <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations">testing their constructs</a>.</li> |
+ | </td> | ||
<td><a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
− | <td> | + | <td>We Improved and characterized variants of the <i>E. coli</i> LldR promoter <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_LldR_promoter">lldPRD-operon</a>, on which there is only a limited amount of information present in the Parts Registry and in the literature.</td> |
<td><a href="http://parts.igem.org/Part:BBa_K822000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | <td><a href="http://parts.igem.org/Part:BBa_K822000"><img src="https://static.igem.org/mediawiki/2015/9/9d/ETH15_Tick.png" WIDTH="50%"></a></td> | ||
</tr> | </tr> |
Revision as of 10:23, 18 September 2015
- Project
- Modeling
- Lab
- Human
Practices - Parts
- About Us
Achievements
We are proud to announce that we achieved the following goals
General Achievements
- We completed the Judging Form
- We created a description of our project in time and documented each aspect of the project on this page.
- Documented 20 parts taken from the Registry of Standard Biological Parts.
Experimental Achievements
- We designed a novel system for detection of circulating tumour cells in blood samples using genetically modified bacteria.
- We designed a genetic circuit that integrates two different cancer specific signals (lactate and AHL)in an AND gate.
- We implemented a method to do single cell analysis of cancer cells by expressing Annexin V in the E. coli outer membrane, which enables them to selectively bind to apoptotic cancer cells.
- We designed 8 synthetic LldR dependent promoters and characterized them. Additionally, the influence of the lacate importer LldP was characterized.
- We documented and submitted two new basic parts to the iGEM parts registry and created a part collection with 14 parts.
- We characterized parts of the natural E. coli lldPRD-operon, on which there is only a limited amount of information present in the Parts Registry and in the literature.
- We designed a chip for future application of our MicroBeacon E. coli.
- We participated in the interlab study.
- Our experiments complied with the safety instructions at the Department of Biosystems Science and Engineering D-BSSE in Basel where our lab is situated.
Modeling Achievements
- We separately modeled two different signals of our cancer detection system, the Lactate Module and the AHL Module.
- We defined and estimated all relevant parameters for our models.
- We integrated the two modules into a Combined Compartment Model to simulate a logical AND gate.
- To account for the diffusion and degradation of signaling molecules under real-world conditions we designed various Reaction-diffusion Models.
- We optimized our model by integrating experimental data gathered by the characterization of our LldR promoter constructs.
- We showed that the successful detection of cancer cells with our system is feasible in principle.
Human Practices Achievements
- We went to two different schools, thaught the children about what DNA is, performed experiments with them and published an article about it in the local newspaper.
- We told the ETH-student magacine polykum about iGEM and gave an interview.
- We collaborated with the team from Stockholm by testing some of their constructs.
- We contributed to the Newsletters from Amoys team, met with the Darmstadt team, helped with a survey from EPFL and provided Colombias team with protocols and advice when their transformations did not work.
- We interviewed many different experts from various fields, such as medical doctors, an expert from the ethics commission, the founder of a start-up or an expert in patents law and integrated the advice and ideas we got from them into the design.
Medal Criteria
We registered for iGEM, had a great summer so far, and now we are looking forward to attending the Giant Jamboree! | Going for it! | |
We completed and submitted the Judging Form | ||
We created a description of our project in time. | ||
We documented all the parts taken from the Registry of Standard Biological Parts | ||
We are going to present a poster and give a talk at the Giant Jamboree. | Going for it! | |
We created this website for you to learn about every aspect of our iGEM project. | ||
We documented and submitted two new basic parts to the iGEM parts registry and created a part collection with 14 parts. | ||
These new parts we also submitted to the iGEM Parts Registry. | ||
We characterized two newly designed hybrid promoters and were able to show an effective combined repression by LldR and LacI. According to our knowledge this has never been attempted before. | ||
Our Human Practices Efforts: |
||
More Human Practices Efforts:
|
||
We Improved and characterized variants of the E. coli LldR promoter lldPRD-operon, on which there is only a limited amount of information present in the Parts Registry and in the literature. |